KYUNGRAN GIBSON: Open Payments
NPI 1649897372 · PORTSMOUTH, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,283 in 53 payments from 15 companies in 2025. Trend: 2023 $1,391 · 2024 $1,278 · 2025 $1,283
Food & beverage: $1,283
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 5 | $312 |
| ABBVIE INC. | 20 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $162 |
| Gilead Sciences, Inc. | 4 | $105 |
| GENZYME CORPORATION | 2 | $102 |
| Ardelyx, Inc. | 2 | $62 |
| Madrigal Pharmaceuticals | 1 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| PFIZER INC. | 2 | $33 |
| Lilly USA, LLC | 1 | $29 |
Products named: VOQUEZNA, ENTYVIO, DUPIXENT, LINZESS, RINVOQ, CREON, IBSRELA, REZDIFFRA.
Industry payments across NH — which companies pay providers there.
